Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

55.45 +1.13 (+2.08%)
Official Closing Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
65 66 Next >
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
2 Cheap High-Yield Dividend Stocks to Buy Now
These two pharma stocks are top-notch passive income vehicles. 
Via The Motley Fool
Big Weeks Ahead For MedTech And Life Science Stocks
It’s a big week for earnings that may change the trajectory of the rally but more than likely will continue the rotation into different sectors. 
Via Talk Markets
Why Immatics Shares Are Rising Today
Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced  
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
From Bristol Myers Squibb
Via Business Wire
Analyst Expectations for Bristol-Myers Squibb's Future
Via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Exposures COVID-19
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government
Johnson & Johnson (NYSE: JNJ) has reportedly taken legal action against the U.S. 
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. 
Via Benzinga
What Does Bristol-Myers Squibb's Debt Look Like?
Via Benzinga
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With BMY
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
Via Benzinga
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That
Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. 
Via Benzinga
Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White
From Bristol Myers Squibb
Via Business Wire
Analyst Expectations for Bristol-Myers Squibb's Future
Via Benzinga
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial
From Bristol Myers Squibb
Via Business Wire
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023
Via Benzinga
Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?
Allarity Therapeutics became the toast of Wall Street Wednesday with positive early clinical data, though ALLR stock remains risky. 
Via InvestorPlace
Allarity Says Initial Data Show Improved Clinical Benefit In Breast Cancer Patients Selected Via Companion Diagnostic
Allarity Therapeutics Inc (NASDAQ: ALLR) announced initial results from its European Phase 2 clinical trial evaluating the efficacy of Ixempra in metastatic breast cancer (mBC) patients selected with... 
Via Benzinga
Evotec Secures US Government Contract For Orthopoxvirus Antibody
The U.S. 
Via Benzinga
3 Spectacular Dividend Stocks to Buy in July
Heat up your portfolio this month with these dividend stocks. 
Via The Motley Fool
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
5 High-Yielding Dividend Stocks That Are Bargain Buys
This is a good time for investors to load up on healthcare companies. 
Via The Motley Fool
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
Survival Rates Improve with SELLAS's New Treatment for Severe Lung Cancer, Phase 1 Study Shows
SELLAS Life Sciences Group Inc (NASDAQ: SLS) released topline data from a Phase 1 trial of its lead clinical candidate, galinpepimut-S (GPS), combined with Bristol Myers Squibb Co (NYSE: BMY) nivolumab... 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.